AI Model Differentiates BCC vs cSCC Subtypes
External validation identifies calibration shift in COBRA cohort.
By
Kathryn Wighton
March 23, 2026
Clinical Scorecard: AI Model Differentiates BCC vs cSCC Subtypes
At a Glance
Category Detail
Condition Basal Cell Carcinoma (BCC) and Cutaneous Squamous Cell Carcinoma (cSCC) Key Mechanisms Weakly supervised deep learning model using clustering-constrained attention and feature extraction from a vision transformer. Target Population Patients with infiltrative basal cell carcinoma and poorly differentiated cutaneous squamous cell carcinoma. Care Setting Dermatopathology
Key Highlights
Model achieved 100% accuracy, sensitivity, and specificity on internal test set. External validation showed AUC of 1.0 in Queensland cohort and 0.92 in COBRA cohort. Attention heatmaps indicated tumor localization in histopathology images. Fine-tuning of HistoGPT model improved accuracy to 98% with high sensitivity and specificity. Calibration and domain adaptation are crucial for reliable deployment across institutions. Guideline-Based Recommendations
Diagnosis
Utilize weakly supervised deep learning models for accurate classification of BCC and cSCC. Management
Implement careful calibration and domain adaptation for model deployment. Monitoring & Follow-up
Regularly assess model performance across different cohorts and settings. Risks
Potential for calibration shifts and performance variation due to diagnostic subtype differences and image quality. Patient & Prescribing Data
Patients with diagnosed BCC and cSCC requiring histopathological evaluation.
Deep learning models can enhance diagnostic accuracy in challenging cases.
Clinical Best Practices
Ensure thorough validation of AI models in diverse clinical settings. Monitor model performance and adjust thresholds based on specific cohort characteristics. Related Resources & Content
